NCT06972498

A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets

A Prospective, Single-Arm, Multicenter Clinical Study on the Efficacy and Safety of Ivosimab Combined With Chemotherapy as Neoadjuvant Therapy in Patients With Resectable pMMR/MSS Colorectal Cancer Liver Metastases

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis.

Detailed description

The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis

Conditions

• Colorectal Cancer With Liver Metastasis

Interventions

Type	Name	Description
DRUG	Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.	Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.

Timeline

• Start date: 2025-07-01
• Primary completion: 2027-12-30
• Completion: 2027-12-30
• First posted: 2025-05-15
• Last updated: 2025-05-15